Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients
Effects of B cell depletion by rituximab, a monoclonal antibody to CD20, were studied in patients with relapsing MS that had not responded optimally to standard immunomodulatory therapies. Flow cytometry demonstrated reduced cerebrospinal fluid (CSF) B cells and T cells in most patients at 6 months...
Saved in:
| Published in | Journal of neuroimmunology Vol. 180; no. 1; pp. 63 - 70 |
|---|---|
| Main Authors | , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Netherlands
Elsevier B.V
01.11.2006
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Effects of B cell depletion by rituximab, a monoclonal antibody to CD20, were studied in patients with relapsing MS that had not responded optimally to standard immunomodulatory therapies. Flow cytometry demonstrated reduced cerebrospinal fluid (CSF) B cells and T cells in most patients at 6 months post-treatment. ELISAs demonstrated modest reductions in serum antibodies to myelin oligodendrocyte glycoprotein and myelin basic protein in some subjects. Beta-interferon neutralizing antibodies were reduced in three subjects, but developed anew after treatment in three others, suggesting caution in considering rituximab as a means to eliminate NABs. In summary, rituximab depleted B cells from CSF at 24 weeks after initial treatment, and this B cell depletion was associated with a reduction in CSF T cells as well. |
|---|---|
| AbstractList | Effects of B cell depletion by rituximab, a monoclonal antibody to CD20, were studied in patients with relapsing MS that had not responded optimally to standard immunomodulatory therapies. Flow cytometry demonstrated reduced cerebrospinal fluid (CSF) B cells and T cells in most patients at 6 months post-treatment. ELISAs demonstrated modest reductions in serum antibodies to myelin oligodendrocyte glycoprotein and myelin basic protein in some subjects. Beta-interferon neutralizing antibodies were reduced in three subjects, but developed anew after treatment in three others, suggesting caution in considering rituximab as a means to eliminate NABs. In summary, rituximab depleted B cells from CSF at 24 weeks after initial treatment, and this B cell depletion was associated with a reduction in CSF T cells as well. Effects of B cell depletion by rituximab, a monoclonal antibody to CD20, were studied in patients with relapsing MS that had not responded optimally to standard immunomodulatory therapies. Flow cytometry demonstrated reduced cerebrospinal fluid (CSF) B cells and T cells in most patients at 6 months post-treatment. ELISAs demonstrated modest reductions in serum antibodies to myelin oligodendrocyte glycoprotein and myelin basic protein in some subjects. Beta-interferon neutralizing antibodies were reduced in three subjects, but developed anew after treatment in three others, suggesting caution in considering rituximab as a means to eliminate NABs. In summary, rituximab depleted B cells from CSF at 24 weeks after initial treatment, and this B cell depletion was associated with a reduction in CSF T cells as well.Effects of B cell depletion by rituximab, a monoclonal antibody to CD20, were studied in patients with relapsing MS that had not responded optimally to standard immunomodulatory therapies. Flow cytometry demonstrated reduced cerebrospinal fluid (CSF) B cells and T cells in most patients at 6 months post-treatment. ELISAs demonstrated modest reductions in serum antibodies to myelin oligodendrocyte glycoprotein and myelin basic protein in some subjects. Beta-interferon neutralizing antibodies were reduced in three subjects, but developed anew after treatment in three others, suggesting caution in considering rituximab as a means to eliminate NABs. In summary, rituximab depleted B cells from CSF at 24 weeks after initial treatment, and this B cell depletion was associated with a reduction in CSF T cells as well. Effects of B cell depletion by rituximab, a monoclonal antibody to CD20, were studied in patients with relapsing MS that had not responded optimally to standard immunomodulatory therapies. Flow cytometry demonstrated reduced cerebrospinal fluid (CSF) B cells and T cells in most patients at 6 months post-treatment. ELISAs demonstrated modest reductions in serum antibodies to myelin oligodendrocyte glycoprotein and myelin basic protein in some subjects. Beta-interferon neutralizing antibodies were reduced in three subjects, but developed anew after treatment in three others, suggesting caution in considering rituximab as a means to eliminate NABs. In summary, rituximab depleted B cells from CSF at 24 weeks after initial treatment, and this B cell depletion was associated with a reduction in CSF T cells as well. |
| Author | Ramsbottom, Michael J. Cross, Anne H. Stark, Jennifer L. Lyons, Jeri-Anne Lauber, Joanne |
| Author_xml | – sequence: 1 givenname: Anne H. surname: Cross fullname: Cross, Anne H. email: crossa@neuro.wustl.edu organization: Box 8111, Department of Neurology, Washington University School of Medicine, 660 S. Euclid Avenue, Saint Louis, MO 63110, USA – sequence: 2 givenname: Jennifer L. surname: Stark fullname: Stark, Jennifer L. organization: Box 8111, Department of Neurology, Washington University School of Medicine, 660 S. Euclid Avenue, Saint Louis, MO 63110, USA – sequence: 3 givenname: Joanne surname: Lauber fullname: Lauber, Joanne organization: Box 8111, Department of Neurology, Washington University School of Medicine, 660 S. Euclid Avenue, Saint Louis, MO 63110, USA – sequence: 4 givenname: Michael J. surname: Ramsbottom fullname: Ramsbottom, Michael J. organization: Box 8111, Department of Neurology, Washington University School of Medicine, 660 S. Euclid Avenue, Saint Louis, MO 63110, USA – sequence: 5 givenname: Jeri-Anne surname: Lyons fullname: Lyons, Jeri-Anne organization: Department of Health Sciences, University of Wisconsin-Milwaukee, Milwaukee, WI, USA |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/16904756$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNUU1r3DAQFSWl2aT9C0Gn3ryVbOvDUEKb0DSBQCGkpx6ELI9bbWXJlezQ_PvI7KYfuWxgQAPz3tObeUfowAcPCJ1QsqaE8neb9cbDHIMd1iUhfL1U2bxAKypFWci6pAdolYGsYKKUh-gopQ0hlFV18wodUt6QWjC-Qt9u7DT_toNucYRuNpDwGTbgXMLad_h211ufmwhtDGm0Xjvcu9l2OPR4mN1kRwc4GQd5bBMe9WTBT-k1etlrl-DN7j1GXy8-3Z5fFtdfPl-df7wuDGNsKoByLoHUnTRVz6gQXS97avpaamFk13LKy5YTToXk2bduql7UdVNK0ZYi99UxOt3qjnM7QGfy31E7Nca8VrxXQVv1_8TbH-p7uFNU8KZidRZ4uxOI4dcMaVKDTcvi2kOYk-KSVkLW-4G0YUQQuQBP_rX0x8vj4TOAbwEm3yxF6P9CiFoSVhv1mLBaElZLlU0mvn9CNHbKBw_Latbtp3_Y0iEHcmchqmRyWAY6G8FMqgt2v8TpEwnjrLdGu59w_xyBBwIK3WY |
| CitedBy_id | crossref_primary_10_4049_jimmunol_1301435 crossref_primary_10_1038_ncprheum0983 crossref_primary_10_1016_j_msard_2016_01_001 crossref_primary_10_4049_jimmunol_180_6_3957 crossref_primary_10_1097_WNF_0b013e3181880359 crossref_primary_10_1371_journal_pone_0066188 crossref_primary_10_1007_s40263_018_0567_8 crossref_primary_10_1016_j_ncl_2023_06_001 crossref_primary_10_1016_j_nurt_2007_07_003 crossref_primary_10_4049_jimmunol_1600089 crossref_primary_10_1189_jlb_0410237 crossref_primary_10_1002_cyto_b_20603 crossref_primary_10_1101_cshperspect_a032037 crossref_primary_10_4049_jimmunol_180_3_1362 crossref_primary_10_1016_j_clim_2011_04_005 crossref_primary_10_1080_14712598_2019_1611778 crossref_primary_10_1186_ar3906 crossref_primary_10_1038_s41598_023_36532_3 crossref_primary_10_1016_j_jneuroim_2013_02_010 crossref_primary_10_1371_journal_pone_0007773 crossref_primary_10_1007_s00115_008_2663_3 crossref_primary_10_1016_j_nrl_2011_02_006 crossref_primary_10_1177_1352458519863983 crossref_primary_10_3389_fimmu_2024_1400641 crossref_primary_10_1586_1744666X_3_4_565 crossref_primary_10_1016_j_biopha_2021_111661 crossref_primary_10_1016_j_clim_2014_02_001 crossref_primary_10_1097_WCO_0b013e3281568b80 crossref_primary_10_1038_nm0608_615 crossref_primary_10_1177_1756286419854986 crossref_primary_10_1016_j_msard_2017_03_013 crossref_primary_10_1007_s00011_022_01622_x crossref_primary_10_1016_j_isci_2020_101380 crossref_primary_10_1586_ern_10_117 crossref_primary_10_1007_s13311_015_0385_3 crossref_primary_10_1111_j_1759_1961_2012_00029_x crossref_primary_10_1016_j_jneuroim_2013_06_002 crossref_primary_10_1212_NXI_0000000000000955 crossref_primary_10_1038_nrneurol_2012_203 crossref_primary_10_1111_ajt_13028 crossref_primary_10_4049_jimmunol_1402236 crossref_primary_10_1172_JCI63842 crossref_primary_10_1016_j_jaci_2017_09_001 crossref_primary_10_1016_S0140_6736_11_61649_8 crossref_primary_10_1177_1352458514561911 crossref_primary_10_1111_ane_12915 crossref_primary_10_1002_eji_200737784 crossref_primary_10_1016_j_cellimm_2018_10_006 crossref_primary_10_1002_ana_21289 crossref_primary_10_1007_s13311_012_0164_3 crossref_primary_10_1016_j_it_2009_11_001 crossref_primary_10_1111_cen3_12671 crossref_primary_10_1177_0883073812456084 crossref_primary_10_1111_cen3_12670 crossref_primary_10_1016_j_jneuroim_2023_578267 crossref_primary_10_1002_acn3_52186 crossref_primary_10_1016_j_msard_2023_104729 crossref_primary_10_1016_j_nrleng_2010_06_001 crossref_primary_10_4045_tidsskr_10_0077 crossref_primary_10_1016_j_clim_2017_07_020 crossref_primary_10_1007_s11910_017_0800_8 crossref_primary_10_1007_s00115_008_2664_2 crossref_primary_10_1007_s13311_015_0410_6 crossref_primary_10_1016_j_clim_2008_01_011 crossref_primary_10_1212_01_CON_0000389940_92283_aa crossref_primary_10_1371_journal_pone_0146971 crossref_primary_10_1002_art_27687 crossref_primary_10_4161_mabs_25439 crossref_primary_10_1007_s10875_009_9335_3 crossref_primary_10_1111_cen3_12160 crossref_primary_10_1016_j_msard_2018_08_032 crossref_primary_10_1016_j_msard_2013_10_003 crossref_primary_10_1016_S0035_3787_07_90481_6 crossref_primary_10_1016_j_ncl_2010_12_009 crossref_primary_10_1177_1756285612474333 crossref_primary_10_1212_NXI_0000000000000975 crossref_primary_10_1016_j_clim_2008_05_002 crossref_primary_10_1038_s41598_024_76969_8 crossref_primary_10_1177_1352458518775550 crossref_primary_10_3389_fimmu_2015_00626 crossref_primary_10_3389_fimmu_2021_676686 crossref_primary_10_1002_ana_21363 crossref_primary_10_4049_jimmunol_1001323 crossref_primary_10_4049_jimmunol_1601649 crossref_primary_10_1016_j_jneuroim_2024_578300 crossref_primary_10_1002_jcp_27860 crossref_primary_10_1080_14712598_2019_1568407 crossref_primary_10_1080_14737175_2017_1245616 crossref_primary_10_1016_j_msard_2019_101419 crossref_primary_10_3389_fimmu_2021_661882 crossref_primary_10_3389_fncel_2023_1189709 crossref_primary_10_1007_s00115_008_2521_3 crossref_primary_10_1111_cen3_12603 crossref_primary_10_3390_app11188557 crossref_primary_10_1186_1742_2094_9_215 crossref_primary_10_3389_fimmu_2015_00517 crossref_primary_10_4049_jimmunol_1100885 crossref_primary_10_1016_j_clim_2015_06_001 crossref_primary_10_1038_s41577_025_01141_w crossref_primary_10_1080_13543784_2016_1221924 crossref_primary_10_1212_WNL_0b013e3181e24373 crossref_primary_10_1177_1352458516664210 crossref_primary_10_1016_j_neuron_2018_01_021 crossref_primary_10_1212_NXI_0000000000000079 crossref_primary_10_1002_ana_24088 crossref_primary_10_1212_WNL_0b013e318239f7ef crossref_primary_10_1212_NXI_0000000000000634 crossref_primary_10_1002_eji_202250033 crossref_primary_10_3390_ijms18102048 crossref_primary_10_1002_eji_202149757 crossref_primary_10_1007_s11010_022_04492_3 crossref_primary_10_3389_fimmu_2015_00642 crossref_primary_10_3389_fimmu_2015_00520 crossref_primary_10_1016_j_clineuro_2010_03_010 crossref_primary_10_3389_fimmu_2019_01821 crossref_primary_10_1016_j_jaut_2019_04_013 crossref_primary_10_1016_j_autrev_2009_08_007 crossref_primary_10_12688_f1000research_7599_1 crossref_primary_10_1002_acn3_94 crossref_primary_10_1007_s00296_007_0471_x crossref_primary_10_1017_S1462399407000397 crossref_primary_10_1212_NXI_0000000000200004 crossref_primary_10_1016_j_autrev_2025_103765 crossref_primary_10_3389_fneur_2022_796933 crossref_primary_10_3390_jcm11154288 crossref_primary_10_1007_s40259_018_0327_9 crossref_primary_10_1016_j_msard_2014_09_213 crossref_primary_10_1212_WNL_0b013e31820d6290 crossref_primary_10_1002_eji_201040516 crossref_primary_10_1097_WCO_0b013e3283391feb crossref_primary_10_1111_j_1600_0404_2007_00958_x crossref_primary_10_3389_fimmu_2022_926318 crossref_primary_10_1111_j_1365_2141_2009_07718_x crossref_primary_10_1016_j_nrleng_2013_12_013 crossref_primary_10_1038_gene_2013_18 crossref_primary_10_3390_toxins2040856 crossref_primary_10_1016_j_msard_2021_102787 crossref_primary_10_1177_1756285616666741 crossref_primary_10_1038_s41572_018_0041_4 crossref_primary_10_17816_ACEN_2018_2_6 crossref_primary_10_3389_fimmu_2023_1004795 crossref_primary_10_3390_ijms25168987 crossref_primary_10_1016_j_clim_2016_10_001 crossref_primary_10_1002_ana_21939 crossref_primary_10_1016_j_drudis_2008_08_003 crossref_primary_10_1097_WCO_0b013e3283398c96 crossref_primary_10_1212_NXI_0000000000200250 crossref_primary_10_4161_mabs_1_6_9884 crossref_primary_10_1084_jem_20130699 crossref_primary_10_1186_1479_5876_9_174 crossref_primary_10_47795_FZHZ8873 crossref_primary_10_1016_S1474_4422_08_70110_8 crossref_primary_10_1212_NXI_0000000000000868 crossref_primary_10_1002_14651858_CD009130_pub3 crossref_primary_10_1007_s12026_007_8009_6 crossref_primary_10_1084_jem_20111675 crossref_primary_10_1073_pnas_2207291120 crossref_primary_10_1007_s40259_024_00696_9 crossref_primary_10_1007_s11910_012_0313_4 crossref_primary_10_1016_j_clim_2024_110262 crossref_primary_10_1080_25785826_2021_1952543 crossref_primary_10_1038_ni0208_117 crossref_primary_10_1016_j_jneuroim_2019_04_017 crossref_primary_10_1038_nrneurol_2013_41 crossref_primary_10_1136_annrheumdis_2012_202253 crossref_primary_10_4049_jimmunol_1400118 crossref_primary_10_1074_jbc_RA120_015595 crossref_primary_10_1186_1742_2094_11_18 crossref_primary_10_1111_j_1529_8027_2011_00334_x crossref_primary_10_1007_s13760_023_02329_4 crossref_primary_10_3109_08916934_2011_616558 crossref_primary_10_1007_s40263_021_00863_4 crossref_primary_10_1586_1744666X_3_5_667 crossref_primary_10_3389_fimmu_2017_01255 crossref_primary_10_1038_s41582_019_0268_z crossref_primary_10_1177_1756285608093945 crossref_primary_10_1186_s40478_020_0885_1 crossref_primary_10_1155_2011_780712 crossref_primary_10_1016_j_achaem_2017_08_003 crossref_primary_10_1016_j_jneuroim_2014_06_015 crossref_primary_10_1038_s41573_020_00092_2 crossref_primary_10_1177_2042098612453849 crossref_primary_10_1097_WNO_0000000000000642 crossref_primary_10_1177_1756285609344375 crossref_primary_10_1007_s40472_014_0020_y crossref_primary_10_1016_j_jneuroim_2021_577676 crossref_primary_10_1016_j_nrl_2013_12_022 crossref_primary_10_1002_ana_25119 crossref_primary_10_1111_j_1749_6632_2011_06272_x crossref_primary_10_1016_j_jneuroim_2022_577935 crossref_primary_10_1016_j_msard_2016_07_011 crossref_primary_10_2217_imt_09_7 crossref_primary_10_1002_glia_70007 crossref_primary_10_1016_j_jaci_2007_11_030 crossref_primary_10_3389_fneur_2018_00554 crossref_primary_10_2165_11537510_000000000_00000 crossref_primary_10_1007_s13311_021_01048_z crossref_primary_10_1016_j_msard_2021_103264 crossref_primary_10_1212_NXI_0000000000000431 crossref_primary_10_1371_journal_pone_0048370 crossref_primary_10_3389_fneur_2020_595547 crossref_primary_10_1007_s40263_020_00704_w crossref_primary_10_1016_j_neurol_2023_12_013 crossref_primary_10_1371_journal_pone_0199694 crossref_primary_10_1016_j_jns_2007_09_019 crossref_primary_10_1007_s11910_008_0065_3 crossref_primary_10_1212_NXI_0000000000000550 crossref_primary_10_3389_fimmu_2015_00565 crossref_primary_10_1007_s13311_015_0402_6 crossref_primary_10_1016_j_ijpharm_2011_12_039 crossref_primary_10_3389_fimmu_2018_00835 crossref_primary_10_1016_j_msard_2014_06_001 crossref_primary_10_1007_s00115_020_00937_6 crossref_primary_10_1212_WNL_0b013e3181c97ed3 crossref_primary_10_3389_fneur_2020_533388 crossref_primary_10_3390_diagnostics12030720 crossref_primary_10_1007_s00415_007_0684_7 crossref_primary_10_21518_ms2024_318 crossref_primary_10_1007_s13365_014_0303_1 crossref_primary_10_1002_ana_25927 crossref_primary_10_1038_s41590_018_0135_x crossref_primary_10_1159_000377675 crossref_primary_10_1177_1756285612461165 crossref_primary_10_2165_0003495_200868170_00004 crossref_primary_10_1111_j_1468_1331_2008_02333_x crossref_primary_10_1111_ane_13045 crossref_primary_10_1016_j_intimp_2008_10_004 crossref_primary_10_1146_annurev_cellbio_100617_062518 crossref_primary_10_1074_jbc_M113_451658 crossref_primary_10_1111_imm_13198 crossref_primary_10_1038_s41598_021_94423_x crossref_primary_10_1016_j_jneuroim_2017_12_009 crossref_primary_10_3390_biomedicines9010083 crossref_primary_10_1182_blood_2007_02_068999 crossref_primary_10_1177_1756285609356135 crossref_primary_10_2165_11596920_000000000_00000 crossref_primary_10_3390_v15102112 crossref_primary_10_1007_s00401_010_0724_8 crossref_primary_10_1007_s11910_007_0035_1 crossref_primary_10_1007_s12035_013_8553_0 crossref_primary_10_1016_j_jneuroim_2012_02_015 crossref_primary_10_1007_s00415_008_0956_x crossref_primary_10_3390_biomedicines7010020 crossref_primary_10_3389_fneur_2017_00104 crossref_primary_10_3390_brainsci12040475 crossref_primary_10_1007_s00415_008_6006_x crossref_primary_10_1126_scitranslmed_abi4632 crossref_primary_10_18454_ACEN_2018_2_6 crossref_primary_10_1002_acn3_377 crossref_primary_10_1155_2024_5383099 crossref_primary_10_1007_s11940_012_0215_4 crossref_primary_10_1172_jci_insight_92724 crossref_primary_10_1016_j_jneuroim_2010_03_015 crossref_primary_10_1182_blood_2007_11_122713 crossref_primary_10_1586_1744666X_3_1_73 crossref_primary_10_1089_jir_2013_0134 crossref_primary_10_1002_acn3_293 crossref_primary_10_3389_fncel_2024_1337339 crossref_primary_10_1038_s41467_019_11556_4 crossref_primary_10_1093_braincomms_fcae021 crossref_primary_10_1212_01_CON_0000293640_98116_18 crossref_primary_10_1586_14737175_8_3_433 crossref_primary_10_36290_uro_2017_027 crossref_primary_10_4049_jimmunol_1302848 crossref_primary_10_1038_nrd2358 crossref_primary_10_1016_j_jneuroim_2007_09_015 crossref_primary_10_1126_scitranslmed_adi0295 crossref_primary_10_2217_14796708_4_2_229 crossref_primary_10_1016_S1169_8330_07_80611_9 crossref_primary_10_3389_fimmu_2021_665718 crossref_primary_10_1016_j_coi_2011_09_003 crossref_primary_10_1007_s13365_012_0080_7 crossref_primary_10_1016_j_jns_2009_10_009 crossref_primary_10_1097_01_wco_0000313360_38306_ab crossref_primary_10_1002_ana_21744 crossref_primary_10_1177_1756285610371146 crossref_primary_10_1002_acn3_52009 crossref_primary_10_1038_ncprheum0950 crossref_primary_10_1016_j_humimm_2019_01_001 crossref_primary_10_1517_14728222_2012_677438 crossref_primary_10_1212_NXI_0000000000200080 crossref_primary_10_1002_jcph_513 crossref_primary_10_1038_s41582_021_00498_5 crossref_primary_10_1177_13524585221122210 crossref_primary_10_1111_imr_12929 crossref_primary_10_1177_1352458515581441 crossref_primary_10_1016_j_mehy_2013_12_015 crossref_primary_10_1007_s40259_013_0011_z crossref_primary_10_1111_cen3_12328 crossref_primary_10_1177_2054358117698667 crossref_primary_10_4049_jimmunol_1302171 crossref_primary_10_1371_journal_pone_0002559 crossref_primary_10_1111_imr_12374 crossref_primary_10_1016_j_imlet_2019_08_004 crossref_primary_10_1016_j_msard_2020_102186 crossref_primary_10_1073_pnas_1915309116 crossref_primary_10_1007_s11940_009_0025_5 crossref_primary_10_1038_jid_2008_178 crossref_primary_10_1093_brain_awy239 crossref_primary_10_1016_j_ddstr_2007_08_005 crossref_primary_10_1111_j_1600_065X_2008_00627_x crossref_primary_10_1111_nan_12199 crossref_primary_10_1016_S1470_2045_09_70161_5 crossref_primary_10_1016_j_jneuroim_2007_10_009 crossref_primary_10_3389_fimmu_2015_00241 crossref_primary_10_4049_jimmunol_179_7_4857 crossref_primary_10_1155_2015_296184 crossref_primary_10_1186_1752_1947_7_262 crossref_primary_10_3389_fimmu_2022_953649 crossref_primary_10_1016_j_jneuroim_2008_01_001 crossref_primary_10_3389_fneur_2021_680581 crossref_primary_10_1007_s40263_022_00951_z crossref_primary_10_1186_1742_2094_8_146 crossref_primary_10_1097_WCO_0b013e32832b4ca1 crossref_primary_10_1586_1744666X_4_5_573 crossref_primary_10_4049_jimmunol_1001393 crossref_primary_10_1212_NXI_0000000000000918 crossref_primary_10_1002_art_23171 crossref_primary_10_1016_j_jns_2007_02_027 crossref_primary_10_1038_s41583_019_0233_2 crossref_primary_10_12688_f1000research_74506_2 crossref_primary_10_1177_2055217315623800 crossref_primary_10_12688_f1000research_74506_1 crossref_primary_10_3109_08916934_2013_856006 crossref_primary_10_1128_JVI_00980_19 crossref_primary_10_1097_01_wco_0000313359_61176_15 crossref_primary_10_12688_f1000research_74506_3 crossref_primary_10_3389_fneur_2020_591894 crossref_primary_10_1016_S2352_3026_21_00167_8 crossref_primary_10_1126_scitranslmed_aab4176 crossref_primary_10_1155_2013_839719 crossref_primary_10_1002_cti2_1437 crossref_primary_10_1016_S1474_4422_17_30048_0 crossref_primary_10_1212_NXI_0000000000000463 crossref_primary_10_1097_WCO_000000000000563 crossref_primary_10_1016_j_bbadis_2010_07_020 crossref_primary_10_1126_scitranslmed_3008930 crossref_primary_10_1186_1741_7015_11_205 crossref_primary_10_5812_archneurosci_30107 |
| Cites_doi | 10.1056/NEJMoa022328 10.1001/archneur.62.10.1620 10.1212/WNL.58.5.824 10.1084/jem.163.1.41 10.1136/jnnp.60.1.27 10.1001/archneur.58.12.2044 10.1002/ana.410270104 10.1002/(SICI)1521-4141(199911)29:11<3432::AID-IMMU3432>3.0.CO;2-2 10.1001/archneur.62.2.258 10.1182/blood.V83.2.435.435 10.1016/0090-1229(85)90092-3 10.1177/135245859500100303 10.1034/j.1600-0404.2002.1o009.x 10.1182/blood-2002-11-3569 10.4049/jimmunol.150.4.1629 10.1126/science.1076071 10.1080/00327487208061467 10.4049/jimmunol.162.8.4455 10.1001/archneur.1973.00490240052009 10.1212/WNL.30.3.240 10.1016/S0165-5728(00)00409-4 10.1212/WNL.33.11.1444 10.4049/jimmunol.171.3.1581 10.1146/annurev.immunol.23.021704.115835 10.1136/jnnp.74.4.485 10.1002/1531-8249(199912)46:6<878::AID-ANA10>3.0.CO;2-Q 10.1212/01.WNL.0000159399.81861.D5 10.1007/BF02678220 10.1016/S0022-510X(98)00086-0 |
| ContentType | Journal Article |
| Copyright | 2006 Elsevier B.V. |
| Copyright_xml | – notice: 2006 Elsevier B.V. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7T5 7TK H94 7X8 5PM |
| DOI | 10.1016/j.jneuroim.2006.06.029 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Immunology Abstracts Neurosciences Abstracts AIDS and Cancer Research Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) AIDS and Cancer Research Abstracts Neurosciences Abstracts Immunology Abstracts MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE AIDS and Cancer Research Abstracts |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Anatomy & Physiology |
| EISSN | 1872-8421 |
| EndPage | 70 |
| ExternalDocumentID | PMC1769354 16904756 10_1016_j_jneuroim_2006_06_029 S0165572806002700 |
| Genre | Clinical Trial, Phase II Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
| GrantInformation_xml | – fundername: NCRR NIH HHS grantid: K24RR017100-02 – fundername: NCRR NIH HHS grantid: M01 RR000036 – fundername: NCRR NIH HHS grantid: MO1 RR00036 – fundername: NCRR NIH HHS grantid: K24 RR017100 |
| GroupedDBID | --- --K --M .1- .FO .GJ .~1 0R~ 1B1 1P~ 1RT 1~. 1~5 29L 4.4 457 4CK 4G. 53G 5GY 5VS 7-5 71M 8P~ 9JM AAAJQ AABNK AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AARKO AATTM AAXKI AAXLA AAXUO AAYWO ABBQC ABCQJ ABFNM ABFRF ABIVO ABJNI ABMAC ABMZM ABTEW ABWVN ABXDB ACDAQ ACGFO ACGFS ACIEU ACIUM ACRLP ACRPL ACVFH ADBBV ADCNI ADEZE ADMUD ADNMO AEBSH AEFWE AEIPS AEKER AENEX AEUPX AEVXI AFJKZ AFPUW AFRHN AFTJW AFXIZ AGCQF AGEKW AGHFR AGQPQ AGUBO AGWIK AGYEJ AHHHB AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRLJ AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV CJTIS CNWQP CS3 DU5 EBS EFJIC EFKBS EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HDW HMG HMK HMO HMQ HVGLF HZ~ IHE J1W KOM L7B LUGTX LX8 M29 M2V M41 MO0 MOBAO N9A O-L O9- OAUVE OP~ OZT P-8 P-9 P2P PC. Q38 R2- ROL RPZ SAE SCC SDF SDG SDP SEL SES SEW SIN SNS SPCBC SSH SSI SSN SSZ T5K UNMZH WUQ XJT Z5R ZGI ~G- AACTN AADPK AAIAV ABLVK ABYKQ AFCTW AFKWA AJBFU AJOXV AMFUW EFLBG LCYCR RIG ZA5 AAYXX AGRNS CITATION CGR CUY CVF ECM EIF NPM 7T5 7TK H94 7X8 5PM |
| ID | FETCH-LOGICAL-c555t-e1668e04d8c3f5177df8f1cf48a7c8db6162b6061786690a93f7449287b273f73 |
| IEDL.DBID | .~1 |
| ISSN | 0165-5728 |
| IngestDate | Thu Aug 21 18:11:44 EDT 2025 Thu Aug 07 15:20:03 EDT 2025 Fri Jul 11 10:05:30 EDT 2025 Wed Feb 19 01:53:42 EST 2025 Tue Jul 01 01:53:13 EDT 2025 Thu Apr 24 23:11:25 EDT 2025 Fri Feb 23 02:27:12 EST 2024 Tue Aug 26 17:48:41 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Multiple sclerosis Myelin basic protein antibodies Treatment Autoantibodies B lymphocytes Rituximab Myelin oligodendrocyte glycoprotein antibodies |
| Language | English |
| License | https://www.elsevier.com/tdm/userlicense/1.0 |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c555t-e1668e04d8c3f5177df8f1cf48a7c8db6162b6061786690a93f7449287b273f73 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Article-2 ObjectType-Feature-1 |
| OpenAccessLink | http://doi.org/10.1016/j.jneuroim.2006.06.029 |
| PMID | 16904756 |
| PQID | 19507084 |
| PQPubID | 23462 |
| PageCount | 8 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_1769354 proquest_miscellaneous_68137844 proquest_miscellaneous_19507084 pubmed_primary_16904756 crossref_primary_10_1016_j_jneuroim_2006_06_029 crossref_citationtrail_10_1016_j_jneuroim_2006_06_029 elsevier_sciencedirect_doi_10_1016_j_jneuroim_2006_06_029 elsevier_clinicalkey_doi_10_1016_j_jneuroim_2006_06_029 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2006-11-01 |
| PublicationDateYYYYMMDD | 2006-11-01 |
| PublicationDate_xml | – month: 11 year: 2006 text: 2006-11-01 day: 01 |
| PublicationDecade | 2000 |
| PublicationPlace | Netherlands |
| PublicationPlace_xml | – name: Netherlands |
| PublicationTitle | Journal of neuroimmunology |
| PublicationTitleAlternate | J Neuroimmunol |
| PublicationYear | 2006 |
| Publisher | Elsevier B.V |
| Publisher_xml | – name: Elsevier B.V |
| References | Deibler, Martenson, Kies (bib7) 1972; 2 Lyons, San, Happ, Cross (bib14) 1999; 29 Grossberg, Kawade (bib9) 1997; 10 Trotter, Rust (bib24) 1989 Zhou, Whitaker (bib30) 1993; 150 Bernasconi, Traggiai, Lanzavecchia (bib3) 2002; 298 Di Gaetano, Cittera, Nota, Vecchi, Grieco, Scanziani, Botto, Introna, Golay (bib8) 2003; 171 Villar, Masjuan, Gonzalez-Porque, Plaza, Sadaba, Roldan, Bootello, Alvarez-Cermeno (bib25) 2002; 58 Krzysiek, Lefevre, Zou, Foussat, Bernard, Portier, Galanaud, Richard (bib12) 1999; 162 Rudick, Medendorp, Namey, Boyle, Fischer (bib20) 1995; 1 Kurtzke (bib13) 1983; 33 Weinshenker, O'Brien, Petterson, Noseworthy, Lucchinetti, Dodick, Pineda, Stevens, Rodriguez (bib28) 1999; 46 Avasarala, Cross, Trotter (bib1) 2001; 58 Sellebjerg, Jalishvili, Christiansen, Garred (bib21) 1998; 157 Walsh, Tourtelotte, Roman, Dreyer (bib27) 1985; 35 Berger, Rubner, Schautzer, Egg, Ulmer, Myringer, Dilitz, Deisenhammer, Reindl (bib2) 2003; 349 Zeman, Kidd, McLean, Kelly, Francis, Miller, Kendall, Rudge, Thompson, McDonald (bib29) 1996; 60 Pestronk, Florence, Miller, Choksi, Al-Lozi, Levin (bib17) 2003; 74 Walsh, Tourtelotte (bib26) 1986; 163 Izquierdo, Angulo, Garcia-Moreno, Gamero, Navarro, Gata, Ruiz-Pena, Paramo (bib11) 2002; 105 Cree, Lamb, Morgan, Chen, Waubant, Genain (bib5) 2005; 64 Tourtellotte, Potvin, Fleming, Murthy, Levy, Syndulko, Potvin (bib23) 1980; 30 Cross, Trotter, Lyons (bib6) 2001; 112 Rodriguez, Lennon (bib19) 1990; 27 Stuve, Cepok, Elias, Saleh, Hartung, Hemmer, Kieseier (bib22) 2005; 62 Bernasconi, Onai, Lanzavecchia (bib4) 2003; 101 Guo, Ward (bib10) 2005; 23 Reff, Carner, Chambers, Chinn, Leonard, Raab, Newman, Hanna, Anderson (bib18) 1994; 83 Monson, Cravens, Frohman, Hawker, Racke (bib15) 2005; 62 Olsson, Link (bib16) 1973; 28 Lyons (10.1016/j.jneuroim.2006.06.029_bib14) 1999; 29 Krzysiek (10.1016/j.jneuroim.2006.06.029_bib12) 1999; 162 Kurtzke (10.1016/j.jneuroim.2006.06.029_bib13) 1983; 33 Walsh (10.1016/j.jneuroim.2006.06.029_bib26) 1986; 163 Grossberg (10.1016/j.jneuroim.2006.06.029_bib9) 1997; 10 Monson (10.1016/j.jneuroim.2006.06.029_bib15) 2005; 62 Bernasconi (10.1016/j.jneuroim.2006.06.029_bib4) 2003; 101 Trotter (10.1016/j.jneuroim.2006.06.029_bib24) 1989 Di Gaetano (10.1016/j.jneuroim.2006.06.029_bib8) 2003; 171 Pestronk (10.1016/j.jneuroim.2006.06.029_bib17) 2003; 74 Rodriguez (10.1016/j.jneuroim.2006.06.029_bib19) 1990; 27 Cross (10.1016/j.jneuroim.2006.06.029_bib6) 2001; 112 Zhou (10.1016/j.jneuroim.2006.06.029_bib30) 1993; 150 Rudick (10.1016/j.jneuroim.2006.06.029_bib20) 1995; 1 Bernasconi (10.1016/j.jneuroim.2006.06.029_bib3) 2002; 298 Olsson (10.1016/j.jneuroim.2006.06.029_bib16) 1973; 28 Stuve (10.1016/j.jneuroim.2006.06.029_bib22) 2005; 62 Avasarala (10.1016/j.jneuroim.2006.06.029_bib1) 2001; 58 Berger (10.1016/j.jneuroim.2006.06.029_bib2) 2003; 349 Walsh (10.1016/j.jneuroim.2006.06.029_bib27) 1985; 35 Tourtellotte (10.1016/j.jneuroim.2006.06.029_bib23) 1980; 30 Cree (10.1016/j.jneuroim.2006.06.029_bib5) 2005; 64 Izquierdo (10.1016/j.jneuroim.2006.06.029_bib11) 2002; 105 Sellebjerg (10.1016/j.jneuroim.2006.06.029_bib21) 1998; 157 Guo (10.1016/j.jneuroim.2006.06.029_bib10) 2005; 23 Zeman (10.1016/j.jneuroim.2006.06.029_bib29) 1996; 60 Weinshenker (10.1016/j.jneuroim.2006.06.029_bib28) 1999; 46 Reff (10.1016/j.jneuroim.2006.06.029_bib18) 1994; 83 Deibler (10.1016/j.jneuroim.2006.06.029_bib7) 1972; 2 Villar (10.1016/j.jneuroim.2006.06.029_bib25) 2002; 58 4623901 - Prep Biochem. 1972;2(2):139-65 3941297 - J Exp Med. 1986 Jan 1;163(1):41-53 12560217 - Blood. 2003 Jun 1;101(11):4500-4 16216948 - Arch Neurol. 2005 Oct;62(10):1620-3 9261553 - Biotherapy. 1997;10(1):93-8 2301922 - Ann Neurol. 1990 Jan;27(1):12-7 15771587 - Annu Rev Immunol. 2005;23:821-52 12640069 - J Neurol Neurosurg Psychiatry. 2003 Apr;74(4):485-9 10201982 - J Immunol. 1999 Apr 15;162(8):4455-63 15824362 - Neurology. 2005 Apr 12;64(7):1270-2 10589540 - Ann Neurol. 1999 Dec;46(6):878-86 7189023 - Neurology. 1980 Mar;30(3):240-4 10556797 - Eur J Immunol. 1999 Nov;29(11):3432-9 9619641 - J Neurol Sci. 1998 May 7;157(2):168-74 12874252 - J Immunol. 2003 Aug 1;171(3):1581-7 15710854 - Arch Neurol. 2005 Feb;62(2):258-64 11108928 - J Neuroimmunol. 2001 Jan 1;112(1-2):1-14 3921302 - Clin Immunol Immunopathol. 1985 Jun;35(3):313-27 7506951 - Blood. 1994 Jan 15;83(2):435-45 9345445 - Mult Scler. 1995 Nov;1(3):150-5 6685237 - Neurology. 1983 Nov;33(11):1444-52 11886357 - Acta Neurol Scand. 2002 Mar;105(3):158-63 8558146 - J Neurol Neurosurg Psychiatry. 1996 Jan;60(1):27-30 11735778 - Arch Neurol. 2001 Dec;58(12):2044-5 4121785 - Arch Neurol. 1973 Jun;28(6):392-9 7679432 - J Immunol. 1993 Feb 15;150(4):1629-42 11889253 - Neurology. 2002 Mar 12;58(5):824-6 12481138 - Science. 2002 Dec 13;298(5601):2199-202 12853586 - N Engl J Med. 2003 Jul 10;349(2):139-45 |
| References_xml | – volume: 58 start-page: 2044 year: 2001 end-page: 2045 ident: bib1 article-title: Oligoclonal band number as a marker for prognosis in multiple sclerosis publication-title: Arch. Neurol. – volume: 150 start-page: 1629 year: 1993 end-page: 1642 ident: bib30 article-title: Specific modulation of T cells and murine experimental allergic encephalomyelitis by monoclonal anti-idiotypic antibodies publication-title: J. Immunol. – volume: 28 start-page: 392 year: 1973 end-page: 399 ident: bib16 article-title: Immunoglobulin abnormalities in multiple sclerosis. Relation to clinical parameters: exacerbations and remission publication-title: Arch. Neurol. – volume: 60 start-page: 27 year: 1996 end-page: 30 ident: bib29 article-title: A study of oligoclonal band negative multiple sclerosis publication-title: J. Neurol. Neurosurg. Psychiatry – volume: 29 start-page: 3432 year: 1999 end-page: 3439 ident: bib14 article-title: B-cells are critical to induction of experimental allergic encephalomyelitis by protein but not by a short encephalitogenic peptide publication-title: Eur. J. Immunol. – volume: 58 start-page: 824 year: 2002 end-page: 826 ident: bib25 article-title: Intrathecal IgM synthesis in neurologic disease: relationship with disability in MS publication-title: Neurology – volume: 74 start-page: 485 year: 2003 end-page: 489 ident: bib17 article-title: Treatment of IgM antibody associated polyneuropathies using rituximab publication-title: J. Neurol. Neurosurg. Psychiatry – volume: 64 start-page: 1270 year: 2005 end-page: 1272 ident: bib5 article-title: An open label study of the effects of rituximab in neuromyelitis optica publication-title: Neurology – volume: 62 start-page: 1620 year: 2005 end-page: 1623 ident: bib22 article-title: Clinical stabilization and effective B-lymphocyte depletion in the cerebrospinal fluid and peripheral blood of a patient with fulminant relapsing-remitting multiple sclerosis publication-title: Arch. Neurol. – volume: 105 start-page: 158 year: 2002 end-page: 163 ident: bib11 article-title: Intrathecal IgG synthesis: marker of progression in multiple sclerosis patients publication-title: Acta Neurol. Scand. – volume: 30 start-page: 240 year: 1980 end-page: 244 ident: bib23 article-title: Multiple sclerosis: measurement and validation of central nervous system IgG synthesis rate publication-title: Neurology – volume: 349 start-page: 139 year: 2003 end-page: 145 ident: bib2 article-title: Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event publication-title: N. Engl. J. Med. – volume: 2 start-page: 139 year: 1972 end-page: 165 ident: bib7 article-title: Large scale preparation of myelin basic protein from central nervous system tissue of several mammalian species publication-title: Prep. Biochem. – volume: 27 start-page: 12 year: 1990 end-page: 17 ident: bib19 article-title: Immunoglobulins promote remyelination in the CNS publication-title: Ann. Neurol. – volume: 157 start-page: 168 year: 1998 end-page: 174 ident: bib21 article-title: Intrathecal activation of the complement system and disability in multiple sclerosis publication-title: J. Neurol. Sci. – volume: 35 start-page: 313 year: 1985 end-page: 327 ident: bib27 article-title: Immunoglobulin G, A, and M-clonal restriction in multiple sclerosis cerebrospinal fluid and serum-analysis by two-dimensional electrophoresis publication-title: Clin. Immunol. Immunopathol. – volume: 23 start-page: 821 year: 2005 end-page: 852 ident: bib10 article-title: Role of C5a in inflammatory responses publication-title: Annu. Rev. Immunol. – volume: 1 start-page: 150 year: 1995 end-page: 155 ident: bib20 article-title: Multiple sclerosis progression in a natural history study: predictive value of cerebrospinal fluid free kappa light chains publication-title: Mult. Scler. – volume: 163 start-page: 41 year: 1986 end-page: 53 ident: bib26 article-title: Temporal invariance and clonal uniformity of brain and cerebrospinal IgG, IgA, and IgM in multiple sclerosis publication-title: J. Exp. Med. – volume: 162 start-page: 4455 year: 1999 end-page: 4463 ident: bib12 article-title: Antigen receptor engagement selectively induces macrophage inflammatory protein-1α and MIP-1β chemokine production in human B cells publication-title: J. Immunol. – volume: 83 start-page: 435 year: 1994 end-page: 445 ident: bib18 article-title: Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20 publication-title: Blood – volume: 46 start-page: 878 year: 1999 end-page: 886 ident: bib28 article-title: A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease publication-title: Ann. Neurol. – volume: 10 start-page: 93 year: 1997 end-page: 98 ident: bib9 article-title: The expression of potency of neutralizing antibodies for interferons and other cytokines publication-title: Biotherapy – volume: 33 start-page: 1444 year: 1983 end-page: 1452 ident: bib13 article-title: Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS) publication-title: Neurology – start-page: 179 year: 1989 end-page: 226 ident: bib24 article-title: Human cerebrospinal fluid immunology publication-title: Cerebrospinal Fluid – volume: 171 start-page: 1581 year: 2003 end-page: 1587 ident: bib8 article-title: Complement activation determines the therapeutic activity of rituxmab in vivo publication-title: J. Immunol. – volume: 62 start-page: 258 year: 2005 end-page: 264 ident: bib15 article-title: Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis publication-title: Arch. Neurol. – volume: 298 start-page: 2199 year: 2002 end-page: 2202 ident: bib3 article-title: Maintenance of serological memory by polyclonal activation of human memory B cells publication-title: Science – volume: 112 start-page: 1 year: 2001 end-page: 14 ident: bib6 article-title: B cells and antibodies in CNS demyelinating disease publication-title: J. Neuroimmunol. – volume: 101 start-page: 4500 year: 2003 end-page: 4504 ident: bib4 article-title: A role for Toll-like receptors in acquired immunity: Upregulation of TLR9 by BCR triggering in naïve B cells and constitutive expression in memory B cells publication-title: Blood – start-page: 179 year: 1989 ident: 10.1016/j.jneuroim.2006.06.029_bib24 article-title: Human cerebrospinal fluid immunology – volume: 349 start-page: 139 year: 2003 ident: 10.1016/j.jneuroim.2006.06.029_bib2 article-title: Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa022328 – volume: 62 start-page: 1620 year: 2005 ident: 10.1016/j.jneuroim.2006.06.029_bib22 article-title: Clinical stabilization and effective B-lymphocyte depletion in the cerebrospinal fluid and peripheral blood of a patient with fulminant relapsing-remitting multiple sclerosis publication-title: Arch. Neurol. doi: 10.1001/archneur.62.10.1620 – volume: 58 start-page: 824 year: 2002 ident: 10.1016/j.jneuroim.2006.06.029_bib25 article-title: Intrathecal IgM synthesis in neurologic disease: relationship with disability in MS publication-title: Neurology doi: 10.1212/WNL.58.5.824 – volume: 163 start-page: 41 year: 1986 ident: 10.1016/j.jneuroim.2006.06.029_bib26 article-title: Temporal invariance and clonal uniformity of brain and cerebrospinal IgG, IgA, and IgM in multiple sclerosis publication-title: J. Exp. Med. doi: 10.1084/jem.163.1.41 – volume: 60 start-page: 27 year: 1996 ident: 10.1016/j.jneuroim.2006.06.029_bib29 article-title: A study of oligoclonal band negative multiple sclerosis publication-title: J. Neurol. Neurosurg. Psychiatry doi: 10.1136/jnnp.60.1.27 – volume: 58 start-page: 2044 year: 2001 ident: 10.1016/j.jneuroim.2006.06.029_bib1 article-title: Oligoclonal band number as a marker for prognosis in multiple sclerosis publication-title: Arch. Neurol. doi: 10.1001/archneur.58.12.2044 – volume: 27 start-page: 12 year: 1990 ident: 10.1016/j.jneuroim.2006.06.029_bib19 article-title: Immunoglobulins promote remyelination in the CNS publication-title: Ann. Neurol. doi: 10.1002/ana.410270104 – volume: 29 start-page: 3432 year: 1999 ident: 10.1016/j.jneuroim.2006.06.029_bib14 article-title: B-cells are critical to induction of experimental allergic encephalomyelitis by protein but not by a short encephalitogenic peptide publication-title: Eur. J. Immunol. doi: 10.1002/(SICI)1521-4141(199911)29:11<3432::AID-IMMU3432>3.0.CO;2-2 – volume: 62 start-page: 258 year: 2005 ident: 10.1016/j.jneuroim.2006.06.029_bib15 article-title: Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis publication-title: Arch. Neurol. doi: 10.1001/archneur.62.2.258 – volume: 83 start-page: 435 year: 1994 ident: 10.1016/j.jneuroim.2006.06.029_bib18 article-title: Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20 publication-title: Blood doi: 10.1182/blood.V83.2.435.435 – volume: 35 start-page: 313 year: 1985 ident: 10.1016/j.jneuroim.2006.06.029_bib27 article-title: Immunoglobulin G, A, and M-clonal restriction in multiple sclerosis cerebrospinal fluid and serum-analysis by two-dimensional electrophoresis publication-title: Clin. Immunol. Immunopathol. doi: 10.1016/0090-1229(85)90092-3 – volume: 1 start-page: 150 year: 1995 ident: 10.1016/j.jneuroim.2006.06.029_bib20 article-title: Multiple sclerosis progression in a natural history study: predictive value of cerebrospinal fluid free kappa light chains publication-title: Mult. Scler. doi: 10.1177/135245859500100303 – volume: 105 start-page: 158 year: 2002 ident: 10.1016/j.jneuroim.2006.06.029_bib11 article-title: Intrathecal IgG synthesis: marker of progression in multiple sclerosis patients publication-title: Acta Neurol. Scand. doi: 10.1034/j.1600-0404.2002.1o009.x – volume: 101 start-page: 4500 year: 2003 ident: 10.1016/j.jneuroim.2006.06.029_bib4 article-title: A role for Toll-like receptors in acquired immunity: Upregulation of TLR9 by BCR triggering in naïve B cells and constitutive expression in memory B cells publication-title: Blood doi: 10.1182/blood-2002-11-3569 – volume: 150 start-page: 1629 year: 1993 ident: 10.1016/j.jneuroim.2006.06.029_bib30 article-title: Specific modulation of T cells and murine experimental allergic encephalomyelitis by monoclonal anti-idiotypic antibodies publication-title: J. Immunol. doi: 10.4049/jimmunol.150.4.1629 – volume: 298 start-page: 2199 year: 2002 ident: 10.1016/j.jneuroim.2006.06.029_bib3 article-title: Maintenance of serological memory by polyclonal activation of human memory B cells publication-title: Science doi: 10.1126/science.1076071 – volume: 2 start-page: 139 year: 1972 ident: 10.1016/j.jneuroim.2006.06.029_bib7 article-title: Large scale preparation of myelin basic protein from central nervous system tissue of several mammalian species publication-title: Prep. Biochem. doi: 10.1080/00327487208061467 – volume: 162 start-page: 4455 year: 1999 ident: 10.1016/j.jneuroim.2006.06.029_bib12 article-title: Antigen receptor engagement selectively induces macrophage inflammatory protein-1α and MIP-1β chemokine production in human B cells publication-title: J. Immunol. doi: 10.4049/jimmunol.162.8.4455 – volume: 28 start-page: 392 year: 1973 ident: 10.1016/j.jneuroim.2006.06.029_bib16 article-title: Immunoglobulin abnormalities in multiple sclerosis. Relation to clinical parameters: exacerbations and remission publication-title: Arch. Neurol. doi: 10.1001/archneur.1973.00490240052009 – volume: 30 start-page: 240 year: 1980 ident: 10.1016/j.jneuroim.2006.06.029_bib23 article-title: Multiple sclerosis: measurement and validation of central nervous system IgG synthesis rate publication-title: Neurology doi: 10.1212/WNL.30.3.240 – volume: 112 start-page: 1 year: 2001 ident: 10.1016/j.jneuroim.2006.06.029_bib6 article-title: B cells and antibodies in CNS demyelinating disease publication-title: J. Neuroimmunol. doi: 10.1016/S0165-5728(00)00409-4 – volume: 33 start-page: 1444 year: 1983 ident: 10.1016/j.jneuroim.2006.06.029_bib13 article-title: Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS) publication-title: Neurology doi: 10.1212/WNL.33.11.1444 – volume: 171 start-page: 1581 year: 2003 ident: 10.1016/j.jneuroim.2006.06.029_bib8 article-title: Complement activation determines the therapeutic activity of rituxmab in vivo publication-title: J. Immunol. doi: 10.4049/jimmunol.171.3.1581 – volume: 23 start-page: 821 year: 2005 ident: 10.1016/j.jneuroim.2006.06.029_bib10 article-title: Role of C5a in inflammatory responses publication-title: Annu. Rev. Immunol. doi: 10.1146/annurev.immunol.23.021704.115835 – volume: 74 start-page: 485 year: 2003 ident: 10.1016/j.jneuroim.2006.06.029_bib17 article-title: Treatment of IgM antibody associated polyneuropathies using rituximab publication-title: J. Neurol. Neurosurg. Psychiatry doi: 10.1136/jnnp.74.4.485 – volume: 46 start-page: 878 year: 1999 ident: 10.1016/j.jneuroim.2006.06.029_bib28 article-title: A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease publication-title: Ann. Neurol. doi: 10.1002/1531-8249(199912)46:6<878::AID-ANA10>3.0.CO;2-Q – volume: 64 start-page: 1270 year: 2005 ident: 10.1016/j.jneuroim.2006.06.029_bib5 article-title: An open label study of the effects of rituximab in neuromyelitis optica publication-title: Neurology doi: 10.1212/01.WNL.0000159399.81861.D5 – volume: 10 start-page: 93 year: 1997 ident: 10.1016/j.jneuroim.2006.06.029_bib9 article-title: The expression of potency of neutralizing antibodies for interferons and other cytokines publication-title: Biotherapy doi: 10.1007/BF02678220 – volume: 157 start-page: 168 year: 1998 ident: 10.1016/j.jneuroim.2006.06.029_bib21 article-title: Intrathecal activation of the complement system and disability in multiple sclerosis publication-title: J. Neurol. Sci. doi: 10.1016/S0022-510X(98)00086-0 – reference: 16216948 - Arch Neurol. 2005 Oct;62(10):1620-3 – reference: 7506951 - Blood. 1994 Jan 15;83(2):435-45 – reference: 12874252 - J Immunol. 2003 Aug 1;171(3):1581-7 – reference: 12853586 - N Engl J Med. 2003 Jul 10;349(2):139-45 – reference: 12560217 - Blood. 2003 Jun 1;101(11):4500-4 – reference: 6685237 - Neurology. 1983 Nov;33(11):1444-52 – reference: 2301922 - Ann Neurol. 1990 Jan;27(1):12-7 – reference: 11108928 - J Neuroimmunol. 2001 Jan 1;112(1-2):1-14 – reference: 11889253 - Neurology. 2002 Mar 12;58(5):824-6 – reference: 3921302 - Clin Immunol Immunopathol. 1985 Jun;35(3):313-27 – reference: 15824362 - Neurology. 2005 Apr 12;64(7):1270-2 – reference: 7679432 - J Immunol. 1993 Feb 15;150(4):1629-42 – reference: 15771587 - Annu Rev Immunol. 2005;23:821-52 – reference: 4623901 - Prep Biochem. 1972;2(2):139-65 – reference: 3941297 - J Exp Med. 1986 Jan 1;163(1):41-53 – reference: 10589540 - Ann Neurol. 1999 Dec;46(6):878-86 – reference: 10556797 - Eur J Immunol. 1999 Nov;29(11):3432-9 – reference: 8558146 - J Neurol Neurosurg Psychiatry. 1996 Jan;60(1):27-30 – reference: 11735778 - Arch Neurol. 2001 Dec;58(12):2044-5 – reference: 10201982 - J Immunol. 1999 Apr 15;162(8):4455-63 – reference: 15710854 - Arch Neurol. 2005 Feb;62(2):258-64 – reference: 12640069 - J Neurol Neurosurg Psychiatry. 2003 Apr;74(4):485-9 – reference: 11886357 - Acta Neurol Scand. 2002 Mar;105(3):158-63 – reference: 9619641 - J Neurol Sci. 1998 May 7;157(2):168-74 – reference: 4121785 - Arch Neurol. 1973 Jun;28(6):392-9 – reference: 9261553 - Biotherapy. 1997;10(1):93-8 – reference: 9345445 - Mult Scler. 1995 Nov;1(3):150-5 – reference: 12481138 - Science. 2002 Dec 13;298(5601):2199-202 – reference: 7189023 - Neurology. 1980 Mar;30(3):240-4 |
| SSID | ssj0015349 |
| Score | 2.377163 |
| Snippet | Effects of B cell depletion by rituximab, a monoclonal antibody to CD20, were studied in patients with relapsing MS that had not responded optimally to... |
| SourceID | pubmedcentral proquest pubmed crossref elsevier |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 63 |
| SubjectTerms | Adult Antibodies, Monoclonal - immunology Antibodies, Monoclonal - pharmacology Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Murine-Derived Antibody Formation - drug effects Antibody Formation - immunology Antigens, CD20 - immunology Autoantibodies Autoantibodies - analysis Autoantibodies - blood Autoantibodies - immunology B lymphocytes B-Lymphocytes - drug effects B-Lymphocytes - immunology Cerebrospinal Fluid - cytology Cerebrospinal Fluid - immunology Down-Regulation - drug effects Down-Regulation - immunology Female Flow Cytometry Glatiramer Acetate Humans Immunity, Cellular - drug effects Immunity, Cellular - immunology Immunologic Factors - immunology Immunologic Factors - pharmacology Immunologic Factors - therapeutic use Immunosuppression - methods Interferon beta-1a Interferon beta-1b Interferon-beta - therapeutic use Male Middle Aged Multiple sclerosis Multiple Sclerosis, Relapsing-Remitting - cerebrospinal fluid Multiple Sclerosis, Relapsing-Remitting - drug therapy Multiple Sclerosis, Relapsing-Remitting - immunology Myelin basic protein antibodies Myelin oligodendrocyte glycoprotein antibodies Myelin Proteins - immunology Peptides - therapeutic use Rituximab T-Lymphocytes - drug effects T-Lymphocytes - immunology Treatment Treatment Outcome |
| Title | Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0165572806002700 https://dx.doi.org/10.1016/j.jneuroim.2006.06.029 https://www.ncbi.nlm.nih.gov/pubmed/16904756 https://www.proquest.com/docview/19507084 https://www.proquest.com/docview/68137844 https://pubmed.ncbi.nlm.nih.gov/PMC1769354 |
| Volume | 180 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3da9swEBelg7GXsbX76D46PYy9uYlqffkxKyvZQvvQtaywByNbElNonBInsL3sb9-dLGfNPuhgYIiJ77AlnU530t3vCHntLLgNqmYZy32V8cKyrDDMZ6owlddSVSwiMZ2cyvEF_3ApLrfIUZ8Lg2GVSfd3Oj1q6_TPIPXm4DqEwUdMxBFYXQmPltQQ_XbOFUr5wfd1mAdM6M4EBuIMqW9kCU8PphE0MszSoQRc0dT84wL1uwH6axzljYXp-AG5nyxKOuo--iHZcs0O2R014E3PvtE3NMZ4xs3zHXL3JB2l75LPZ2G5-hpmpqILhG91LX1LcRu_paax9DzdhwZuFuA4Y30RfI-_WgVL5572oYi0hdfC49DSBNLaPiIXx-_Oj8ZZqrSQ1UKIZeaYlNoNudV17gVTynrtWe25NqrWtpJMHlYSrR0twZ02Re4V5wV4WxWYP17lj8l2M2_cU0LB3MpRcdQI8yONN4y7SiqrcyOZY3aPiL57yzrBkGM1jKuyjzeblv2wYI1MWeJ1WOyRwZrvugPiuJVD9aNX9mmmoBhLWCtu5SzWnBvC-E-8r3pBKWGm4liZxs1XbYkFd9VQ879TSM1ypTlQPOkE62dLode5EhLatCFyawJECd980oQvES2cYbVLwZ_9R5uek3tx5ymmYL4g28vFyr0EW2xZ7cfJtk_ujN5Pxqf4Ozn7NPkBWw04Ew |
| linkProvider | Elsevier |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELaqIgEXBC2P8qoPiFu668avHEtFtUC3B9hKlThYdmKLrLrZarMrwYXfzozjLF0eKhKSD1EyI8ev8Yw98w0hr3wFZoMqWcby4DJeVCwrLAuZKqwLWirHIhLT-EyOzvn7C3GxRY77WBh0q0yyv5PpUVqnN4PUm4Oruh58wkAcgdmV8GpJDcFuv8Vh-WIag4Pvaz8PWNGdDgzUGZJfCxOeHkwjamQ9S7cSUKKu-ccd6ncN9FdHyms708l9ci-plPSo--sHZMs3O2T3qAFzevaNvqbRyTOenu-Q2-N0l75LPn-sl6uv9cw6ukD8Vt_SNxTP8Vtqm4pO0nPdwMMCLGdMMIL1hMtVXdF5oL0vIm2hWvhctzShtLYPyfnJ28nxKEupFrJSCLHMPJNS-yGvdJkHwZSqgg6sDFxbVerKSSYPnUR1R0uwp22RB8V5AeaWA_0nqPwR2W7mjX9CKOhbOUqOEnF-pA2Wce-kqnRuJfOs2iOi715TJhxyTIdxaXqHs6nphwWTZEqD5bDYI4M131WHxHEjh-pHz_RxpiAZDWwWN3IWa86N2fhPvPv9RDGwVHGsbOPnq9Zgxl011PzvFFKzXGkOFI-7ifWzpdDrXAkJbdqYcmsChAnf_NLUXyJcOMN0l4I__Y827ZM7o8n41Jy-O_vwjNyNx1AxHvM52V4uVv4FKGZL9zIuvB9kdTf- |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Rituximab+reduces+B+cells+and+T+cells+in+cerebrospinal+fluid+of+multiple+sclerosis+patients&rft.jtitle=Journal+of+neuroimmunology&rft.au=Cross%2C+Anne+H.&rft.au=Stark%2C+Jennifer+L.&rft.au=Lauber%2C+Joanne&rft.au=Ramsbottom%2C+Michael+J.&rft.date=2006-11-01&rft.pub=Elsevier+B.V&rft.issn=0165-5728&rft.eissn=1872-8421&rft.volume=180&rft.issue=1&rft.spage=63&rft.epage=70&rft_id=info:doi/10.1016%2Fj.jneuroim.2006.06.029&rft.externalDocID=S0165572806002700 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0165-5728&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0165-5728&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0165-5728&client=summon |